- Publicerad
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.
Redeye
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.
Redeye